| Literature DB >> 35386441 |
Fatih Kurtuldu1,2, Nurshen Mutlu1,2, Aldo R Boccaccini2, Dušan Galusek1,3.
Abstract
The incorporation of gallium into bioactive materials has been reported to enhance osteogenesis, to influence blood clotting, and to induce anti-cancer and anti-bacterial activity. Gallium-doped biomaterials prepared by various techniques include melt-derived and sol-gel-derived bioactive glasses, calcium phosphate bioceramics, metals and coatings. In this review, we summarize the recently reported developments in antibacterial, anticancer, osteogenesis, and hemostasis properties of Ga-doped biomaterials and briefly outline the mechanisms leading to Ga biological effects. The key finding is that gallium addition to biomaterials has great potential for treating bone-related diseases since it can be efficiently transferred to the desired region at a controllable rate. Besides, it can be used as a potential substitute for antibiotics for the inhibition of infections during the initial and advanced phases of the wound healing process. Ga is also used as an anticancer agent due to the increased concentration of gallium around excessive cell proliferation (tumor) sites. Moreover, we highlight the possibility to design different therapeutic approaches aimed at increasing the efficiency of the use of gallium containing bioactive materials for multifunctional applications.Entities:
Keywords: Antibacterial; Bioactive materials; Cancer treatment; Hemostasis; Osteogenesis
Year: 2022 PMID: 35386441 PMCID: PMC8964984 DOI: 10.1016/j.bioactmat.2021.12.034
Source DB: PubMed Journal: Bioact Mater ISSN: 2452-199X
Fig. 1Biomedical application areas of gallium containing biomaterials (Created with BioRender.com).
Fig. 2Schematic outline of anticancer activity of Ga. Fe and Ga are up-taken by the cells through transferrin and transferrin independent routes. Fe and Ga are unloaded in an acidic endosome and transfer to the pool, which can be inhibited by Ga. The Fe pool is used for ribonucleotide reductase and mitochondrial activity (Created with BioRender.com).
Fig. 3Schematic illustration of antibacterial activity of Ga. Ga crosses the cytoplasmic membrane of bacteria by using Fe-uptake routes using transferrin, homophora and siderophore. Ga cannot be reduced and critical functions such as DNA synthesis, respiration, and oxidative stress response are interrupted by Ga (Created with BioRender.com).
Fig. 4Illustration of the fabrication/synthesis of melt derived and sol-gel derived gallium containing bioactive glasses (Created with BioRender.com).
Gallium containing melt derived bioactive glasses.
| Composition (% mol) | Investigated Properties | Application Area | Features | Ref. |
|---|---|---|---|---|
| 70SiO2-(30-x)CaO-xGa2O3 x = 2, 4% | Evaluation of gallium influence on glass structure by FTIR, NMR. Characterization of glass by XRF, XRD, DSC, SEM. In vitro ion release study in distilled water and SBF. In vitro biocompatibility and angiogenesis assay using MG-63. Evaluation of antibacterial activity against | Slightly increased cell viability. Improved VEGF secretion. Antibacterial activity. | [ | |
| 42SiO2-(40-x)ZnO–10Na2O–8CaO-xGa2O3 x = 0, 8, 16% | Characterization of glass using XRD, particle size analysis, XPS, DTA. Structural evaluation by Raman spectroscopy and NMR. In vitro degradation study in ultra-pure water. | Predominantly network former, may exist in modifying role | [ | |
| 46.2SiO2-24.3Na2O-26.9CaO-2.6P2O5-xGa2O3 x = 1.0, 1.6, 3.5 | Glass characterization by XRD, ESEM, EDS. In vitro ion release and bioactivity study in SBF. | Bioactive response. Improved chemical durability. | [ | |
| 45.7SiO2-24.1Na2O-26.6CaO-2.6P2O5-1.0Ga2O3 | Functionalization with TEOS and APTS. In vitro degradation and bioactivity study in SBF. Characterization of functional groups with FTIR, ESEM-EDS. | Bioactive response | [ | |
| (46.1–3x)SiO2-26.9CaO-24.4Na2O-2.6P2O5-xGa2O3 x = 1, 2, 3% | Characterization of glass using SEM, XRD, FTIR, XRD. In vitro bioactivity evaluation in SBF. Dissolution study in ultra-pure water. Cell viability assay using human osteosarcoma (Saos-2) cells and primary normal human osteoblast | Bone cancer treatment | Decreased osteosarcoma viability. No effect on osteoblast viability | [ |
| 45P2O5–14CaO–35Na2O-3Ga2O3 | Evaluation of antibacterial activity using | Periodontitis treatment | Lower MMP-13 activity | [ |
| 45P2O5-xCaO-(47-x)Na2O-3Ga2O3–5Ag2O x = 10, 11, 12 | In vitro degradation test in deionized water. Evaluation of antibacterial activity and anti-biofilm properties using | Combat infections | Antibacterial activity and anti-biofilm formation | [ |
| P2O5–MgO–CaO–Na2O–Ga2O3–CeO2, up to 7% CeO2 or Ga2O3 | Characterization of glass by Raman, XRD, FTIR, In vitro degradation study in deionized water. In vitro cell viability evaluation using bone marrow stromal cells (ST2). Evaluation of antibacterial activity against | Tissue engineering and wound healing | Less glass solubility. Decreased cell viability | [ |
| 45P2O5–16CaO-(39-x)Na2O-xGa2O3 x = 1, 3, 5 | Degradation study in deionized water. In vitro antibacterial assay against | Bone tissue | Less glass solubility. Improved antibacterial activity | [ |
| 45P2O5-xCaO-(47-x)Na2O-3Ga2O3–5Ag2Ox = 10, 11, 12 | Degradation study in deionized water. In vitro antibacterial assay against | Periodontal therapy | Improved antibacterial activity | [ |
| (52-x)B2O3–16ZnO–14Na2O–12CaO–6P2O5-xGa2O3 x = 0, 2.5, 5, 10, 15 in wt. % | Characterization of glass by XRD, SEM, DSC. Structural influence evaluation by FTIR, Raman, NMR. In vitro ion release test in distilled water. Evaluation of antibacterial activity against | Increase in ratio of BO3 to BO4, decreased glass solubility. Improved antibacterial activity | [ | |
| (52-x)B2O3–16ZnO–14Na2O–12CaO–6P2O5-xGa2O3 x = 0, 2.5, 5, 10, 15 in wt. % | In vitro degradation study in distilled water. Evaluation of cell viability using pre-osteoblast MC3T3-E1 and osteosarcoma SaOS-2 cells | Osteosarcoma related bone graft | Improved osteoblasts viability with lower Ga content. Decreased osteosarcomas viability using containing 5% wt. Ga2O3 glass extract for 7 days | [ |
| B2O3–CaO–Na2O–K2O–MgO–P2O5–Ce2O3(1, 3, 5%)/Ga2O3(1, 5%) | Characterization of scaffold and powder by SEM-EDX, XRD, FTIR, DTA-TG. In vitro bioactivity and degradation studies in SBF. Determination of mechanical properties of sintered glass powder by Vickers microhardness test. | Bone tissue | Lower degradation rate. Bioactive response | [ |
| B2O3–CaO–Na2O–K2O–MgO–P2O5–Ce2O3/Ga2O3/V2O5 up to 5 wt% | In vivo implantation into a connective tissue of subcutaneous area of rats. Evaluation of in vitro antibacterial activity against | Soft tissue | Lower angiogenesis potential. No antibacterial activity i | [ |
| 48SiO2-(40-x)ZnO–12CaO-xGa2O3 x = 8, 16% | Characterization of glass by XRD, DTA, XPS. Evaluation of mechanical properties by compressive strength, biaxial flexural strength test. | Anti-cancerous bone cement | No significant change in Tg. Lower compressive strength. | [ |
| 42SiO2–10Na2O–8CaO-(40-x)ZnO-xGa2O3 x = 0, 8, 16% | Characterization of glass using particle size and surface area analysis. Characterization of composite by SEM and EDAX. Determination of swelling characteristic of a hydrogel. In vitro ion release in PBS. In vitro cytotoxicity evaluation using L-929 mouse fibroblast and MC3T3-E1 human osteoblast | Bone void filling material | No significant change in cell viability up to 30 days incubation. Max. 4.7 mg/L Ga release within 30 days. | [ |
| 42SiO2–10Na2O–8CaO-(40-x)ZnO-xGa2O3 x = 0, 8, 16% | Characterization of composite via CP MAS-NMR, TEM, DSC. In vitro MG-63 osteosarcoma cell viability assay. In vitro ion release test in ultra-pure water. | Bone void filling material | Decreased osteosarcoma viability using obtained extracts from glasses and composites after 30 days | [ |
| 48SiO2–12CaO–32ZnO-8Ga2O3 | Characterization of composite by SEM-EDX. In vitro ion release study in PBS and SBF. In vitro bioactivity evaluation in SBF. In vitro ion penetration test into bone tissue matrix. Antibacterial test against | Bone tissue | Delayed CaP precipitation. Improved antibacterial activity. Low concentration of Ga absorbed into bone. | [ |
| 42SiO2–10Na2O–8CaO-(40-x)ZnO-xGa2O3, x = 0, 8, 16% | Characterization of glass by particle size analysis, surface area analysis. In vitro degradation test in ultra-pure water and PBS. Antibacterial efficiency study against | Bone void filling | Improved antifungal and antibacterial activity in viscous environment. | [ |
| 33SiO2-(18-x)-Al2O3–23CaO–11P2O5–15CaCl2 | Characterization of alginate, glasses and composite by gel permeation chorography, NMR, FTIR, XRD, laser diffraction, DTA-TG, helium pycnometer, EXAFS, BET, XPS, FESEM, zeta potential. Evaluation of mechanical properties of composite by compression testing in cell medium. In vitro degradation study in DMEM. In vitro cytotoxicity evaluation using BASMCs and BAECs. | Cardiovascular tissue engineering | Matching stiffness with soft tissue. Slow and tunable gelation rate. No significant cell death. | [ |
| B2O3–CaO–K2O–MgO–Na2O–P2O51Ag2O/CeO2/CuO/Fe2O3/Ga2O3/SrO/Y2O3/ZnO in wt.% | In vitro degradation study in SBF. Evaluation of neuronal survival and neurite outgrowth in dorsal root ganglion from E11 chicks. | Peripheral nerve regeneration | Improved outgrowth of neurons and ratio of survival of neurons. Decreased survival of support cells | [ |
| P2O5–CaO–MgO–Na2O–Ga2O3, up to 6 %Ga2O3 | Evaluation of the structural influence of gallium addition by NMR, FTIR, micro-Raman. Mechanical properties by nano-indentation. | Orthopedic/dental implant | Improved mechanical properties. | [ |
Gallium containing sol-gel derived bioactive glasses.
| Composition (% mol) | Investigated Properties | Application Area | Features | Ref. |
|---|---|---|---|---|
| 70SiO2-(30-x)CaO-xGa2O3 x = 2, 4% | Evaluation of gallium influence on glass structure by FTIR, NMR. Characterization of glass by XRF, XRD, DSC, SEM. In vitro ion release study in distilled water and SBF. In vitro biocompatibility and angiogenesis assay using MG-63. Evaluation of antibacterial activity against | Lower cell viability compared to melt derived counterpart. Improved VEGF secretion. | [ | |
| (80-x)SiO2–15CaO–5P2O5-x(Ce2O3/Ga2O3/ZnO) x = up to 7% | Characterization of glasses using NMR, XRD, FTIR, SEM, ICP. In vitro bioactivity in SBF. | Bone tissue | Reduction of glass network connectivity. Decreased bioactivity at high Ga content. | [ |
| 70SiO2–15CaO–10P2O5-5Ga2O3 | Characterization of glass by XRD, EDX, BET, TEM, NMR. In vitro bioactivity test in SBF. In vitro degradation study in SBF, DMEM, and Todd Hewitt Broth culture medium. | Tissue engineering | Lower network connectivity and fast bioactive response with higher amount of modifier ions. | [ |
| 80SiO2–15CaO–5P2O5- 3.5Ga2O3/3.5CeO2/7ZnO | Characterization of glasses using XRD, TEM, BET, DTA-TG. In vitro bioactivity test in SBF. | Bone tissue | Decreased in mesopore order and textural properties. Bioactive response. | [ |
| 77.3SiO2-14.5CaO-4.8P2O5-3.4Ga2O3 | Characterization of glasses via XRD, FTIR, ESEM, EDS, XPS, BET, CO adsorption, DMP Adsorption/Desorption. In vitro bioactivity and ion release test in SBF. | Bone tissue | Delayed bioactive response. Enhanced surface acidity. Slower glass dissolution | [ |
| (80-x)SiO2–15CaO–5P2O5- (x = 0.2, 1.0)Ce2O3/Ga2O3/(x = 0.4, 2.0)ZnO | Characterization of scaffolds via XRD, BET, SEM, DTA-TG. In vitro bioactivity in SBF. | Bone tissue | Decreased surface area and pore volume. Bioactive response. Suitable pore structure | [ |
| (80-x)SiO2–15CaO–5P2O5-xCe2O3/Ga2O3/ZnO x up to 4% | In vitro curcumin release test in SBF. Characterization of glasses by XRD, TEM, EDS, BET, DTA-TG. In vitro bioactivity in SBF. | Drug delivery | Exhibited suitable textural properties. Optimum drug loading and release at lowest Ga incorporation. Quick bioactive response. | [ |
| (80-x)SiO2–15CaO–5P2O5-xGa2O3 x = 1, 2, 3 mol% | Characterization of glasses by BET, XRD, TEM, SEM-EDS, FTIR, zeta potential measurements. In vitro ion release and bioactivity test in Tris-HCl buffer solution. In vitro blood plasma coagulation assay. Absorption efficiency test in PBS. In vitro thrombus formation test. In vitro platelet adhesion test. Evaluation of antibacterial activity against | Wound infection and hemostatic agent | Improved textural properties at lowest Ga content. Enhanced blood coagulation, thrombus generation, platelet adhesion and cell viability at lowest Ga content. Improved antibacterial activity. | [ |
| 58SiO2–31CaO–5P2O5-6Ga2O3 85SiO2-8.4CaO–5P2O5-1.6Ga2O3 | Characterization of glass by XRD, BET, XRF, NMR, TEM. In vitro bioactivity test in SBF. In vitro degradation study in MEM. In vitro cell viability, proliferation, early differentiation test using preosteoblast (MC3T3-E1) cells. In vitro osteoclast culture and viability test using the mouse monocyte cells (RAW 264.7) | Bone substitute in osteoporotic patients | Bioactive response. Decreased textural properties. Enhanced early differentiation of osteoblasts. Disturbed osteoclatogenesis. | [ |
| (80-x)SiO2–15CaO–5P2O5-xGa2O3 x = 1% | Characterization of glass by FESEM, HRTEM, XRD, BET, Zeta sizer. Evaluation of water absorption capacity. In vitro degradation study in Tris-HCl. In vitro coagulation, thrombin generation, platelet adhesion, and thrombus formation assay. In vitro biocompatibility study using human dermal fibroblast cells. Hemostatic features compared with commercial products (Celox™ and QuicClot Advanced Clotting Sponge Plus™) | Hemostatic applications | Enhanced platelet adhesion. Improved contact activation (larger platelet aggregates, more extensive platelet pseudopodia). Accelerated clotting cascade. Increased cell viability. | [ |
| 77.3SiO2-14.5CaO-4.8P2O5-3.4Ga2O3 | Characterization of glass by NMR, DTA-TG, XRD, HRTEM, BET, FTIR. Determination of drug release (curcumin) by UV–Vis. In vitro degradation test in SBF. | Drug delivery | Having textural properties to load large molecules (i.e., curcumin). Controlled drug release. Stabilization of Ga ions with curcumin. Local drug delivery. | [ |
| 80SiO2–15CaO–5P2O5 3.5Ga2O3/3.5Ce2O3/7ZnO | Characterization of glass by XRD, BET, SEM, EDX. In vitro bioactivity test in SBF. Determination of the antibacterial activity of scaffold against | Bone tissue | Decreased textural properties and mesoporous order. Delayed bioactive response. No antibacterial activity. | [ |
| 70SiO2–15CaO–5P2O5-10Ga2O3 | Glass characterization by XRD, EDX, FTIR, BET. In vitro degradation test in distilled water. Determination of mechanical properties by microhardness measurement. In vitro cell viability assay using human dental pulp stem cells | Orthodontic treatment | Decreased degree of enamel demineralization. Increased microhardness. No significant change of adhesive remnant index, cell viability and bacteria viability. | [ |
| 60SiO2-(40-x)CaO-xGa2O3 | Glass characterization by SEM, BET, ICP-OES, XRD, FTIR. In vitro bioactivity test in SBF. In vitro degradation test in PBS. In vitro cell viability using MG-63. Antibacterial activity test against | Drug delivery, bone tissue | Disorder mesoporous structure. Bioactive response. Slow release of Ga ions. Improved cell viability and antibacterial activity. | [ |
Fig. 5Effect of gallium in the silicate glass structure.
Fig. 6a) SEM images ofMBGs after immersion in SBF for 7 days, b) fluorescence microscopy images of MC3T3-E1 preosteoblast like cells after direct contact with MBGs for 4 days, c) proliferation of MC3T3-E1 cells in direct contact with MBGs after 1, 4 and 7 days incubation (*p < 0.05, #p < 0.01) and their ALP activity after 7 day incubation with MBGs (**p < 0.05), d) RAW 264.7 mouse monocytes viability after 4 days incubation with direct contact of 10 mg/mL MBGs in the presence of 20 nM RANKL and effect of MBGs on the TRAP expression of mature osteoclasts (normalized results corresponding to the control, *p < 0.05). Reproduced with permission from ref. [78]. Copyright 2018 Elsevier.
Fig. 7a) Schematic illustration of fabrication process of chitosan and Ga containing MBGs composite by freeze drying, b) evaluation of blood clotting ability of fabricated composites compared to CeloxRapid gauze (CXR) and pure chitosan (pure CHT): (1) lower hemoglobin absorbance as an indicator of higher blood clotting rate, (2–7) images of hemoglobin leakage from negative control, pure chitosan, composites containing 10%, 30%, 50% bioactive glass and CXR respectively, c) evaluation of platelet adhesion after 30 min Incubation of platelet rich plasma(1), morphology of adhered platelets (2–7) in the same order, d) evaluation of thrombus formation after 30 min Incubation with whole blood, (*,‡p < 0.05 compared with CHT and CXR, respectively). Reprinted with permission from ref. [17] Copyright 2017 American Chemical Society.
Gallium containing calcium phosphate (CaP) bioceramics.
| Production Method | Composition/Phase (% mol) | Investigated Properties | Features | Ref. |
|---|---|---|---|---|
| Precipitation method | Hydroxyapatite (Ga2O3 up to 11.0 mass %) | Characterization of ceramic by SEM, EDX, TG, DTA, XRD, and thermomechanical properties. | Ga does not cause changes in the crystal structure of HA. | [ |
| Precipitation method | Hydroxyapatite (molar ratio Ga/Ca) equal to 0.025, 0.05, and 0.1) | Characterization of ceramic by XRD, FTIR, BET, SEM, TG. Chemical composition and ion release behavior measured by ICP-OES. Cell viability assay using adipose-Derived Stem Cells (ASCs). Determination of the antibacterial activity of the scaffold against | Enhanced the antibacterial activity and osteoblast differentiation. | [ |
| Precipitation method | Hydroxyapatite | In vivo biocompatibility study using albino Wistar male rats. | Improved the repair of bone defects. | [ |
| Precipitation method and solid-state reaction | Hydroxyapatite (Ga content up to 0.35 mass%) | Characterization of ceramic by TEM, ICP-OES, XRD, FTIR, and NMR. Cell viability assay using BALB/c 3T3 cells. Antibacterial effect against | Ga affected the crystal structure of HA. Showed antibacterial effect against | [ |
| Solid-state reaction | Calcium Phosphate Cement, Ca10.5-1.5xGax(PO4)7 | Characterization of ceramic by NMR, XRD, SEM. | Injectable. Increased new bone formation in osteoporosis sheep model. | [ |
| Solid-state reaction | Calcium phosphate ceramics, (Ca + Ga)/P molar ratio of 1.515 and a Ga/Ca molar ratio in the 0–0.08 range. | Characterization of ceramic by XRD, solid-state NMR, | Improved mechanical properties. Showed a dose-dependent antiresorptive effect. | [ |
| Solid-state reaction | β-TCP (up to 7.5 mol% Ga) | Characterization of ceramic by XRD and SEM. The cytocompatibility and in vitro osteoblastic differentiation were performed with mouse bone mesenchymal stem cells (mBMSCs). Osteoclast differentiation with RAW 264.7 cells. | Improved compressive strength. Suppressed | [ |
| Solid-state reaction | Calcium phosphate ceramics, (Ca + Ga)/P molar ratio of 1.515 and a Ga/Ca molar ratio in the 0–0.08 range. | Characterization of ceramic by XRD, solid-state NMR, SEM, and EDX. Cell viability assay using RAW 264.7 cell line. In vivo biocompatibility study using rabbits. | Ga release increased preferentially in the presence of osteoclasts. Showed a good interface between implant and newly formed bone in rabbit model. | [ |
| Solid-state reaction | Calcium phosphate ceramics, (Ca + Ga)/P molar ratio of 1.515 and a Ga/Ca molar ratio in the 0–0.08 range. | Characterization of ceramic by XRD, solid-state NMR, SEM, and EDX. Cell viability assays using primary human osteoblasts and monocytes cells. In vivo bone reconstructive study using a murine bone defect-healing model. | Suppressed | [ |
| Solid-state reaction | β-TCP and Gallium containing phosphate glasses | Characterization of ceramic by XRD, SEM, and measurement of compressive stress of the scaffolds. In vitro osteogenic behaviors assessed by mBMSCs cell line. In vitro osteoclastic behavior evaluated using RAW 264.7 cell line. | Improved cell proliferation. Enhanced the late osteogenic markers. Suppressed osteoclast differentiation. | [ |
Fig. 8a) Compressive strength of Ga doped TCP bioceramics (*p < 0.05, &:significantly different from all the other samples), b) proliferation and c) ALP activity of mBMSCs after treatment of extracts of the samples, d) osteoclastic activity related genes expressions (*p < 0.05), e) fluorescence images of RAW 264.7 cells after 3 days of treatment with extracts of the samples (cytoskeleton and nuclei arestained in green and blue, respectively). Reproduced with permission from ref. [132]. Copyright 2020 Elsevier.
Fig. 9Antibacterial activity of metal samples against S. epidermidis, S. aureus, and E.coli, a) fluorescence images of biofilm formation on Mg, Mg-0.1Ga, Ti and blank after 1 and 3 days (live and dead bacteria are stained in green and red respectively), b) live/dead staining of hMSCs in direct contact with metal materials after 24 h incubation, c) in vivo antibacterial activity of implanted metal rods retrieved from a mouse at day 5 in post-op time period, d) cross-sectional micrographs of implanted rods (mature bone tissue and fibrous tissue are stained in red and blue, respectively). Reproduced with permission from ref. [166]. Copyright 2019 Elsevier.